Exacis Entered into an Option to License Agreement with Eterna for Four iPSC Derived NK Cell and T Cell Therapies
Shots:
- Eterna to get the right to license up to four off-the-shelf, iPSC-derived NK & T cell cancer treatments developed using Exacis' mRNA-reprogrammed iPSCs engineered with Exacis' mRNA-based gene editing platform. The agreement includes an up front license fee, development & commercialization milestones along with royalties
- Exacis' allogeneic cell therapies are made from mRNA-reprogrammed iPSCs engineered for stealthing and performance using mRNA-based gene editing incl. mRNA vector RiboSlice and nuclease NoveSlice, differentiated into NK & T cells targeted at virtually any tumor Ag
- Exacis' ExaNK & ExaCAR-NK are designed to be used alone or in combination with Abs or NK cell engagers
Ref: PRNewswire | Image: Exacis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
